Edwards Lifesciences Corporation (NYSE:EW) – Analysts at Jefferies Group issued their Q1 2018 EPS estimates for shares of Edwards Lifesciences in a report released on Tuesday. Jefferies Group analyst R. Denhoy expects that the medical research company will earn $1.03 per share for the quarter. Jefferies Group also issued estimates for Edwards Lifesciences’ Q2 2018 earnings at $1.06 EPS, Q3 2018 earnings at $1.01 EPS, Q4 2018 earnings at $1.09 EPS, FY2019 earnings at $4.86 EPS and FY2020 earnings at $5.40 EPS.

Other research analysts have also recently issued research reports about the stock. SunTrust Banks set a $124.00 price objective on shares of Edwards Lifesciences and gave the company a “buy” rating in a report on Wednesday, October 25th. Canaccord Genuity restated a “buy” rating and issued a $135.00 price objective (down previously from $155.00) on shares of Edwards Lifesciences in a report on Wednesday, October 25th. Cowen restated a “buy” rating and issued a $135.00 price objective on shares of Edwards Lifesciences in a report on Thursday, October 12th. Royal Bank Of Canada restated a “buy” rating and issued a $130.00 price objective on shares of Edwards Lifesciences in a report on Friday, September 1st. Finally, BMO Capital Markets restated a “buy” rating and issued a $132.00 price objective on shares of Edwards Lifesciences in a report on Friday, September 1st. Seven investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $125.53.

Shares of Edwards Lifesciences (NYSE EW) traded down $0.75 during mid-day trading on Wednesday, hitting $113.05. 1,774,100 shares of the company were exchanged, compared to its average volume of 1,641,731. The company has a quick ratio of 2.76, a current ratio of 3.49 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $24,082.35, a PE ratio of 31.52, a P/E/G ratio of 2.04 and a beta of 0.51. Edwards Lifesciences has a 52-week low of $81.85 and a 52-week high of $121.45.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, October 24th. The medical research company reported $0.84 EPS for the quarter, missing analysts’ consensus estimates of $0.86 by ($0.02). The firm had revenue of $821.50 million for the quarter, compared to analysts’ expectations of $833.85 million. Edwards Lifesciences had a return on equity of 27.22% and a net margin of 22.47%. Edwards Lifesciences’s revenue for the quarter was up 11.1% on a year-over-year basis. During the same period last year, the firm earned $0.68 earnings per share.

In other news, VP Donald E. Bobo, Jr. sold 5,300 shares of the business’s stock in a transaction that occurred on Friday, September 29th. The shares were sold at an average price of $108.86, for a total transaction of $576,958.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Schack Wesley W. Von sold 1,000 shares of the business’s stock in a transaction that occurred on Thursday, November 9th. The stock was sold at an average price of $104.15, for a total transaction of $104,150.00. Following the sale, the director now owns 2,622 shares of the company’s stock, valued at approximately $273,081.30. The disclosure for this sale can be found here. Insiders have sold a total of 172,480 shares of company stock valued at $18,548,810 in the last 90 days. Insiders own 2.13% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in EW. Janney Montgomery Scott LLC raised its position in Edwards Lifesciences by 10.3% in the 2nd quarter. Janney Montgomery Scott LLC now owns 9,184 shares of the medical research company’s stock valued at $1,086,000 after purchasing an additional 860 shares during the last quarter. Bbva Compass Bancshares Inc. raised its position in Edwards Lifesciences by 3.3% in the 2nd quarter. Bbva Compass Bancshares Inc. now owns 2,860 shares of the medical research company’s stock valued at $338,000 after purchasing an additional 92 shares during the last quarter. IFP Advisors Inc raised its position in Edwards Lifesciences by 7.1% in the 2nd quarter. IFP Advisors Inc now owns 6,736 shares of the medical research company’s stock valued at $796,000 after purchasing an additional 447 shares during the last quarter. Pictet Asset Management Ltd. raised its position in Edwards Lifesciences by 27.8% in the 2nd quarter. Pictet Asset Management Ltd. now owns 321,648 shares of the medical research company’s stock valued at $37,012,000 after purchasing an additional 69,896 shares during the last quarter. Finally, Baxter Bros Inc. raised its position in Edwards Lifesciences by 45.0% in the 2nd quarter. Baxter Bros Inc. now owns 25,949 shares of the medical research company’s stock valued at $3,068,000 after purchasing an additional 8,050 shares during the last quarter. Hedge funds and other institutional investors own 81.63% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was first reported by American Banking News and is the property of of American Banking News. If you are viewing this story on another website, it was illegally copied and reposted in violation of international trademark and copyright legislation. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/12/06/edwards-lifesciences-corporation-forecasted-to-post-q1-2018-earnings-of-1-03-per-share-ew.html.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Earnings History and Estimates for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.